[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscular-dystrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscular-dystrophy":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,53,85,119,145,177,207,232,260,283,320,351,387,410],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100126292","braingate2-feasibility-study-of-an-intracortical-neural-interface-system-for-persons-with-tetraplegia-100126292",false,"NCT00912041","BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia","BrainGate2","Inclusion Criteria:\n\n* Clinical diagnosis of spinal cord injury, brainstem stroke, muscular dystrophy, amyotrophic lateral sclerosis or other motor neuron disorders\n* Complete or incomplete tetraplegia (quadriplegia)\n* Must live within a three-hour drive of the Study site\n* (There are additional inclusion criteria)\n\nExclusion Criteria:\n\n* Visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses\n* Chronic oral or intravenous steroids or immunosuppressive therapy\n* Other serious disease or disorder that could seriously affect ability to participate in the study\n* (There are additional exclusion criteria)","ALL","18 Years","80 Years",{"count":20,"type":21},27,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.",[27,28,29,30,31,32],"Tetraplegia","Spinal Cord Injuries","Amyotrophic Lateral Sclerosis","Brain Stem Infarctions","Locked in Syndrome","Muscular Dystrophy",[34,35,36,37,38,39],"Brain computer interface","Assistive device","Environmental control","Communication device","quadriplegia","tetraplegia","RECRUITING","2026-05-28",{"date":43,"type":44},"2026-06-01","ACTUAL",{"date":46,"type":4},"2009-05",{"date":48,"type":21},"2038-12",{"name":50,"class":51},"Leigh R. Hochberg, MD, PhD.","OTHER",6,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":16,"minAge":17,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100617696","assessment-of-a-portable-digital-device-for-quantified-analysis-of-markerless-walking-in-volunteers-with-neuromuscular-diseases-or-asymptomatic-volunteers-100617696","NCT07321977","Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers","Myokinesis","* All volunteers\n\n  * Age between 18 and 65\n  * Ambulatory\n  * Informed consent to participate in the study\n  * Member of or beneficiary of a social security system\n* Volunteers with a neuromuscular disease\n\n  * Confirmed diagnosis of a neuromuscular disease of genetic origin (medical document to be provided upon enrollment in the study with proof of diagnosis) belonging to the list above.\n  * Ability to walk for 2 minutes without assistance.\n  * Ability to stand up from a chair with armrests at least 3 times in 30 seconds.\n  * Ability to climb an inclined plane independently or with assistance to access the movement analysis room.\n\nExclusion Criteria\n\n* All volunteers\n\n  * Individuals under guardianship, curatorship, or legal protection\n  * Pregnant or breastfeeding women\n  * Non-ambulatory individuals\n  * Individuals with epilepsy\n  * Skin conditions preventing the placement of VICON motion sensors\n* Asymptomatic volunteers\n\n  * Unstable respiratory or cardiac problems\n  * Neurological, musculoskeletal, or psychiatric problems\n* Volunteers with a neuromuscular disease\n\n  * Recent trauma or serious falls (≤ 6 months)\n  * Individuals who have fallen more than twice in the past year and at least once in the past three months\n  * Use of assistive devices such as rigid knee braces or walkers\n  * Unstable cardiomyopathy\n  * Individuals awaiting diagnosis\n\nExclusion criteria\n\n* Inability to comply with the protocol requirements\n* Medical or social conditions that could interfere with the study, as determined by the coordinating investigator or co-investigators.",true,"65 Years",{"count":63,"type":21},30,[24],"In recent years, knowledge of neuromuscular diseases has advanced considerably, and new therapeutic avenues are beginning to emerge. The proliferation of clinical trials has created a need to identify biomarkers that are both sensitive to changes and specific to the disease. Current gait tests only consider the time factor and not the evolution of the patient's biomechanics, which may prove insufficient for patients whose symptoms generally progress slowly. Quantifying gait parameters in neuromuscular patients therefore appears necessary. This is why we propose to study markerless gait analysis in this population, which would allow for simple and effective monitoring of kinematic parameters without resorting to complex equipment incompatible with routine clinical practice.",[67,68,32,69],"Spinal Muscular Atrophy (SMA)","Charcot-Marie-Tooth","Myotonic Dystrophy",[71,72,73,74],"gait analysis","neuromuscular","disease","markerless","2026-05-18",{"date":77,"type":44},"2026-05-19",{"date":79,"type":44},"2026-03-03",{"date":81,"type":21},"2027-01-06",{"name":83,"class":51},"Institut de Myologie, France",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":92,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":98,"conditions":99,"keywords":106,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":84},"100538429","phase-2-vasodilator-and-exercise-study-for-dmd-vaso-rex-100538429","NCT06290713","Vasodilator and Exercise Study for DMD (VASO-REx)","Vasodilators and Exercise as Adjuvant Therapy for Duchenne Muscular Dystrophy (VASO-REx Study)","Inclusion Criteria:\n\n* Diagnosis of DMD confirmed by genetic report\n* Minimum entry age of 6.0 years old\n* Ambulatory\n* On stable glucocorticoid regimen (for \\> 3 months)\n\nExclusion Criteria:\n\n* Contraindication to a Magnetic resonance Imaging examination (e.g. severe claustrophobia, magnetic implants, unable\u002Funwilling to perform test)\n* Presence of unstable medical problems, including severe cardiomyopathy, left ventricular ejection fraction \\\u003C45%, cardiac conduction abnormalities as evidenced on ECG, uncontrolled seizure disorder, uncontrolled hypo or hypertension\n* Presence of a secondary condition that impacts muscle function or muscle metabolism (e.g., myasthenia gravis, endocrine disorder, mitochondrial disease)\n* Presence of a secondary condition leading to developmental delay or impaired motor control (e.g., cerebral palsy) or previous history of unprovoked rhabdomyolysis\n* Contraindications to phosphodiesterase 5 inhibitors (use of nitrates, alpha-adrenergic blockers, other phosphodiesterase 5 inhibitors) or other medications known to modulate blood flow or muscle metabolism\n* Participation in currently approved FDA trials or other investigational clinical trials during the period of the study","MALE","6 Years",{"count":95,"type":21},50,[97],"PHASE2","Examining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve cardiovascular health) and tadalafil, an FDA-approved vasodilator (to optimize blood flow and muscle perfusion which is impaired and often overlooked in DMD). Target: improved muscle function, vascular health, and DMD treatment.",[100,101,32,102,103,104,105],"Duchenne Muscular Dystrophy","Duchenne Disease","Muscular Dystrophy in Children","Vasodilation","Exercise","DMD",[105,107,108,109],"Tadalafil","Drug and Exercise Intervention","Treatment Strategy","2026-05-12",{"date":112,"type":44},"2026-05-15",{"date":114,"type":44},"2024-06-05",{"date":116,"type":21},"2026-11",{"name":118,"class":51},"University of Florida",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":84},"100488777","nomad-p-kafo-study-100488777","NCT05644522","Nomad P-KAFO Study","Power Forward Study: A Cross-Sector, Multisite Clinical Trial of a Powered Knee-Ankle-Foot Orthosis","Inclusion Criteria:\n\n* Regular and compliant use of a unilateral or bilateral KAFO or SCO or other passive KAFOs for impairment due to neurological or neuromuscular disease, orthopedic disease, or trauma\n* Cognitive ability to understand and follow the study protocol; willingness to provide informed consent\n* Willing to wear and charge an activity monitor for three-months home trials.\n\nExclusion Criteria:\n\n* Flexion contracture in the knee and\u002For hip joint in excess of 15 degrees\n* Non-correctable knee varus\u002Fvalgus in excess of 15 degrees\n* Severe spasticity\n* Inability to stabilize the trunk with or without assistive devices (crutches, canes, etc.)","89 Years",{"count":128,"type":21},36,[24],"The goal of this clinical trial is to evaluate the impact of using the Nomad powered KAFO in people who have had a musculoskeletal or neurological injury that has affected their ability to walk. The main questions it aims to answer are to quantify the effectiveness of the Nomad in improving mobility, balance, frequency of falls, and quality of life in individuals with lower-extremity impairments compared to their own brace, over three months of daily home and community use.\n\nParticipants will:\n\n* Wear a sensor that records everyday activities and mobility.\n* Perform measures of mobility and different activities of participation using their own brace.\n* Perform measures of mobility and different activities of participation using the Nomad powered KAFO",[132,133,28,134,32,135],"Cerebrovascular Accident","Post-polio Syndrome","Multiple Sclerosis","Paralysis","2026-05-07",{"date":138,"type":44},"2026-05-11",{"date":140,"type":44},"2024-03-01",{"date":142,"type":21},"2027-12",{"name":144,"class":51},"Shirley Ryan AbilityLab",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":60,"sex":16,"minAge":17,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":155,"conditions":156,"keywords":160,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":84},"100457544","investigational-use-of-neuromuscular-ultrasound-100457544","NCT05237973","Investigational Use of Neuromuscular Ultrasound","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Healthy Volunteers-Adults\n\n   1. Healthy adults, male or female, aged 18 years old or older,\n   2. In good general health as evidenced by medical history, medical conditions under control such as hypertension acceptable.\n   3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n   4. Ability of subject to understand and the willingness to sign a written informed consent document.\n2. Participants with neuromuscular disorders\n\n   1. Adults, male or female, aged 18 years old or older,\n   2. Diagnosed with a neuromuscular disorder or have signs and symptoms of nerve or muscle disorder or neuromuscular diaphragm dysfunction.\n   3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n   4. Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n1. Healthy Volunteers-Adults\n\n   History of stroke, muscle disorders, peripheral neuropathy, or spine surgery\n2. Participants with neuromuscular disorders\n\nNo clinical evidence of a neuromuscular disorder on clinical evaluation.","110 Years",{"count":153,"type":21},150,"OBSERVATIONAL","Background:\n\nCurrent techniques used to measure the health and function of a person s nerves and muscles are generally effective, but they do have limits. Researchers are looking for ways to improve the ability to observe nerves and muscles and how they function in this natural history protocol.\n\nObjective:\n\nTo study the use of ultrasound (sound waves) to learn more about nerves and muscles.\n\nEligibility:\n\nHealthy adults, aged 18 and older, with no history of stroke, nerve or muscular disorders, or spine surgery are also needed. A smaller population of adults aged 18 and older who have a neuromuscular disorder or show symptoms of nerve or muscle disorder will also be evaluated.\n\nDesign:\n\nParticipants will be screened with a medical record review.\n\nParticipants will have up to 5 outpatient clinic visits. Most participants will have 1 or 2 visits. Visits will last for less than 3-4 hours each.\n\nDuring each visit, participants will give a brief medical history and have a physical exam.\n\nParticipants will have ultrasounds to get pictures and measurements of their nerves and muscles. Gel will be applied to their skin. A probe will be placed on the skin surface. Sound waves sent through the probe will be used to create pictures.\n\nParticipants may have nerve conduction studies. Wires will be taped to the skin surface near a muscle or nerve in the arm or leg. The nerve will be stimulated with a small electric current that feels like a rubber band flick. The response will be recorded through the wires.",[32,157,158,159],"Peripheral Neuropathy","Motor Neuron Disorder","Normal Physiology",[161,162,163,164,165,166],"Neuromuscular","Ultrasound","Elastography","Muscle","Nerve","Natural History","2026-04-21",{"date":169,"type":44},"2026-04-22",{"date":171,"type":44},"2022-04-18",{"date":173,"type":21},"2026-08-03",{"name":175,"class":176},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":60,"sex":16,"minAge":17,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":84},"100634694","amino-acids-and-exercise-in-fshd-100634694","NCT07543016","Amino Acids and Exercise in FSHD","Amino Acid Supplementation and Physical Exercise in Facioscapulohumeral Muscular Dystrophy: Effects on Body Composition and Physical Efficiency in a Model of Muscular Disease","Inclusion Criteria:\n\n1. Subjects of both sexes with a diagnosis of FSHD, confirmed by genetic testing.\n2. Age between 18 and 50 years.\n3. Belonging to clinical category A among the four defined in the Comprehensive Clinical Evaluation Form. These patients present the most characteristic signs of the disease: muscle weakness of the facial and scapular girdle.\n4. Clinical score ranging from 2 to 5.\n5. Preserved ability to walk at the time of enrollment.\n6. Absence of central or peripheral nervous system involvement based on neurological history and physical examination.\n7. Absence of scoliosis, limb contractures, and tendon retractions.\n\nExclusion Criteria:\n\n1. Use of beta-blocker medications;\n2. Psychological or psychiatric disorders;\n3. Musculoskeletal injuries that impair the ability to perform physical exercise;\n4. Recent medication adjustment, use of drugs that may affect fatigue, or use of fatigue-stimulating agents (e.g., Modafinil, amantadine);\n5. Ongoing participation in another clinical investigation involving a medical device or drug, or participation in such a study completed less than 30 days prior;\n6. Pregnant or breastfeeding women;\n7. Patients unable to understand the purpose and conditions of the study and unable to provide informed consent;\n8. Presence of additional diseases that may interfere with measurements;\n9. Patients deprived of liberty or under legal guardianship.\n\nHealthy participants will be age- and sex-matched adults without neuromuscular disease:\n\n1. no chronic disease;\n2. no neuromuscular disorders;\n3. Same age range.","50 Years",{"count":186,"type":21},48,[24],"This study evaluates whether amino acid supplementation, combined with a structured diet and exercise program, improves body composition (increased muscle mass and reduced fat mass) and physical performance in individuals with facioscapulohumeral muscular dystrophy (FSHD). The study also compares responses to the intervention between individuals with FSHD and healthy individuals matched for age and sex.",[190,32],"FSH Muscular Dystrophy",[192,193,194,195,196,197,198],"amino acids supplementation","muscular dystrophy","amino acids","exercise","facioscapulohumeral muscular dystrophy","exercise training","nutritional supplementation","2026-04-17",{"date":167,"type":44},{"date":202,"type":44},"2026-04-08",{"date":204,"type":21},"2029-04",{"name":206,"class":51},"University of Pavia",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":214,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":218,"conditions":219,"keywords":223,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":4,"leadSponsor":230,"locationsCount":231},"100057066","study-of-inherited-neurological-disorders-100057066","NCT00004568","Study of Inherited Neurological Disorders","Clinical and Molecular Manifestations of Inherited Neurological Disorders","* Participants include those with inherited neurological conditions based on the training and research needs of the Neurogenetics Branch program. There is no logical limit; however the total number of participants that can be enrolled in the protocol will be restricted. No more than 3,500 participants with either diagnosed or undiagnosed neurological conditions and their unaffected relatives will be enrolled in this evaluation and diagnostic protocol.\n\nINCLUSION CRITERIA:\n\nParticipants will be eligible if they:\n\n* Have either a known or suspected, inherited neurological disease, OR are an unaffected relative (first-, second-, third, or higher degree relative) of a participant with a genetic neurological disease.\n* Have the ability to understand and sign an informed consent or have a parent\u002Flegal guardian to do so if they are minor children or a legal guardian to provide consent for adults without consent capacity.\n* Aged 2 years and above.\n\nEXCLUSION CRITERIA:\n\nParticipants will not be eligible if they:\n\n-Have a systemic disease that compromises the ability to provide adequate neurologic examination or diagnosis.An example of this would be a contagious disease that would compromise our ability to do an adequate neurological exam.","2 Years","120 Years",{"count":217,"type":21},3500,"This study is designed to learn more about the natural history of inherited neurological disorders and the role of heredity in their development. It will examine the genetics, symptoms, disease progression, treatment, and psychological and behavioral impact of diseases in the following categories: hereditary peripheral neuropathies; hereditary myopathies; muscular dystrophies; hereditary motor neuron disorders; mitochondrial myopathies; hereditary neurocognitive disorders; inherited neurological disorders without known diagnosis; and others. Many of these diseases, which affect the brain, spinal cord, muscles, and nerves, are rare and poorly understood.\n\nChildren and adults of all ages with various inherited neurological disorders may be eligible for this study. Participants will undergo a detailed medical and family history, and a family tree will be drawn. They will also have a physical and neurological examination that may include blood test and urine tests, an EEG (brain wave recordings), psychological tests, and speech and language and rehabilitation evaluations. A blood sample or skin biopsy may be taken for genetic testing. Depending on the individual patient s symptoms, imaging tests such as X-rays, CT or MRI scans and muscle and nerve testing may also be done.\n\nInformation from this study may provide a better understanding of the genetic underpinnings of these disorders, contributing to improved diagnosis, treatment, and genetic counseling, and perhaps leading to additional studies in these areas.",[220,221,32,222],"Motor Neuron Disease","Muscular Disease","Peripheral Nervous System Disease",[224,32,220],"Myopathy","2026-04-11",{"date":227,"type":44},"2026-04-14",{"date":229,"type":44},"2000-02-18",{"name":175,"class":176},2,{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":92,"minAge":240,"maxAge":17,"enrollmentInfo":241,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":243,"conditions":244,"keywords":248,"overallStatus":250,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":84},"100632302","a-multicenter-cohort-study-of-duchenne-and-becker-muscular-dystrophy-in-western-chinese-children-100632302","NCT07511920","A Multicenter Cohort Study of Duchenne and Becker Muscular Dystrophy in Western Chinese Children","A Real-World, Multicenter Cohort Study on the Natural History of Duchenne and Becker Muscular Dystrophy in Children From Western China","WEST-DBMD","Inclusion Criteria:\n\n* Male participants with genetically confirmed diagnosis of Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD)\n* Age range: 1 to 18 years old (adjust to your actual age limit)\n* Ability to complete study assessments and follow-up visits\n* Participants or legal guardians provide written informed consent\n\nExclusion Criteria:\n\n* Participants with other neuromuscular disorders that may confound natural history data\n* Participation in another interventional clinical trial that could affect disease progression\n* Severe comorbidities that prevent completion of study assessments\n* Inability to provide informed consent or comply with study procedures","1 Year",{"count":242,"type":21},500,"This is a prospective, multicenter, longitudinal observational cohort study aimed at understanding the progression of Duchenne Muscular Dystrophy (DMD). The primary objective is to identify and integrate key biomarkers from multiple sources-including motor function assessments, body composition (muscle and fat distribution), clinical laboratory tests, and cardiopulmonary imaging-to delineate comprehensive disease trajectories. By analyzing how these factors change over time in a large cohort, the study seeks to develop a robust model that can identify patterns of disease progression. The ultimate goal is to generate evidence that may aid in forecasting individual patient outcomes and inform the future development of personalized rehabilitation and therapeutic strategies.",[245,32,246,247],"Muscular Dystrophy, Becker","Muscular Dystrophy (DMD)","Muscular Dystrophy, Duchenne",[249],"Duchenne Muscular Dystrophy; Becker Muscular Dystrophy; Natural History; Multicenter Cohort Study; China; Predictive Model","NOT_YET_RECRUITING","2026-03-30",{"date":253,"type":44},"2026-04-06",{"date":255,"type":21},"2026-04-20",{"date":257,"type":21},"2028-12-31",{"name":259,"class":51},"West China Second University Hospital",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":250,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":84},"100475403","ibci-optimization-for-veterans-with-paralysis-100475403","NCT05470478","iBCI Optimization for Veterans With Paralysis","Enhancement and Optimization of a Mobile iBCI for Veterans With Paralysis","Inclusion Criteria:\n\n* Inclusion criteria are extensive and are determined by the associated BrainGate IDE(clinicaltrials.gov # NCT00912041)\n* Informally, participants will be tetraplegic or anarthric with little or no functional use of the arms and legs\n\nExclusion Criteria:\n\n* Exclusion criteria are extensive and are determined by the associated BrainGate IDE(clinicaltrials.gov # NCT00912041).",{"count":231,"type":21},[24],"VA research has been advancing a high-performance brain-computer interface (BCI) to improve independence for Veterans and others living with tetraplegia or the inability to speak resulting from amyotrophic lateral sclerosis, spinal cord injury or stoke. In this project, the investigators enhance deep learning neural network decoders and multi-state gesture decoding for increased accuracy and reliability and deploy them on a battery-powered mobile BCI device for independent use of computers and touch-enabled mobile devices at home. The accuracy and usability of the mobile iBCI will be evaluated with participants already enrolled separately in the investigational clinical trial of the BrainGate neural interface.",[271,29,30,272,32],"Spinal Cord Injury","Locked-in Syndrome","2026-02-19",{"date":275,"type":44},"2026-02-23",{"date":277,"type":21},"2026-06-16",{"date":279,"type":21},"2027-06-30",{"name":281,"class":282},"VA Office of Research and Development","FED",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":61,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":294,"conditions":295,"keywords":304,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":52},"100456966","phase-1-a-study-to-evaluate-the-safety-of-ab-1003-previously-lion-101-in-subjects-with-genetic-confirmation-of-lgmd2ir9-part1-100456966","NCT05230459","A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I\u002FR9 (Part1)","A Two-part Multicenter Study: a Randomized, Double-blind, Placebo-controlled Dose-escalation Safety Phase (Part 1) Followed by Double-blind, Placebo-controlled, Adaptive Phase (Part 2) Study to Evaluate the Safety and Efficacy of AB-1003 in Adult Subjects With LGMD2I\u002FR9 Mutations in the Gene Encoding Fukutin Related Protein (FKRP)","Inclusion Criteria:\n\n1. Male and female subjects aged 18 and 65 years with clinical diagnosis of LGMD2I\u002FR9 and confirmation of FKRP gene mutation.\n2. Ability to walk\u002Frun 10 meters in \\\u003C30 seconds.\n3. Able to understand and comply with all study procedures.\n4. Sexually active females of childbearing potential and female and male partners of male subjects receiving study intervention must use a barrier method of contraception for the first 6 months after dosing.\n\nExclusion Criteria:\n\n1. Significant cardiomyopathy as defined by echocardiogram (left ventricular ejection fraction \\\u003C40%), evidence of conduction defect (increased PR and RR intervals, left bundle branch block and QTcF \\>480m\u002Fsec), NYHA Class 3 or 4 heart failure, or MRI gadolinium enhancement evidence of clinically important myocardial fibrosis.\n2. Contraindication to MRI or hypersensitivity to contrast dyes, shellfish or iodine.\n3. Implanted spinal rods, cardiac pacemaker or other implantation that would distort cardiac MRI images.\n4. History of active, ongoing chronic liver disease (e.g. hepatitis, HIV-related liver disease, hemochromatosis, steatosis, etc.) or abnormal liver function tests (abnormal GGT and\u002For abnormal total\u002Fdirect bilirubin \\>upper limit of normal \\[ULN\\] and\u002For elevated AST and ALT \\>2 ULN).\n5. Abnormal renal function (GFR \\\u003C60 ml\u002Fmin, using the Modification of Diet in Renal Disease equation).\n6. Any life-threatening disease, including malignant neoplasms and medical history or malignant neoplasms within the past 5 years prior to screening (except basal and squamous cell skin cancer).\n7. In the opinion of the investigator, a pre-existing medical condition that predisposes the subject to risks that outweighs the potential benefits.\n8. Requirement for daytime ventilatory support.\n9. Change in glucocorticosteroid treatment within 3 months prior to screening visit.\n10. Exposure to another investigational drug within 3 months prior to study treatment or any previous treatment with gene therapy.\n11. Ongoing participation in any other therapeutic clinical trial.\n12. Neutralizing antibody titer to AAV9 \\>1:5.\n13. Female subjects who are pregnant, plan to become pregnant in the next 12 months, or breastfeeding.",{"count":291,"type":21},10,[293,97],"PHASE1","The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I\u002FR9 (LGMD2I\u002FR9). Participants will be treated in sequential, dose-level cohorts. (Part 1)",[296,297,298,32,299,300,301,302,303],"Limb Girdle Muscular Dystrophy","Limb-Girdle Muscular Dystrophy Type 2","LGMD2I","LGMD2","LGMD","FKRP","FKRP Mutation","Fukutin Related Protein",[305,298,306,307,301,308,309],"gene therapy","LGMD2I\u002FR9","gene augmentation therapy","fukutin related protein","FKRP mutation","2026-02-18",{"date":312,"type":44},"2026-02-20",{"date":314,"type":44},"2023-05-15",{"date":316,"type":21},"2032-12",{"name":318,"class":319},"AskBio Inc","INDUSTRY",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":16,"minAge":327,"maxAge":328,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":332,"conditions":333,"keywords":337,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":84},"100495085","evaluating-long-term-use-of-a-pediatric-robotic-exoskeleton-prexagilik-to-improve-gait-in-children-with-movement-disorders-100495085","NCT05726591","Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX\u002FAgilik) to Improve Gait in Children With Movement Disorders","A Phase I\u002FII Trial Evaluating Long-Term Use of a Pediatric Robotic Exoskeleton (P.REX\u002FAgilik) to Improve Gait in Children With Movement Disorders","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Provision of signed and dated separate informed consent and assent forms for screening purposes. Upon inclusion in the protocol, provision of signed and dated informed consent and assent forms to begin participation in the study will be necessary.\n* Stated willingness to comply with all study procedures and availability for the duration of the study, or alternatively, ability to do so based on parent report and physician observation during history and physical examination.\n* Age 3 to 17 years old.\n* Have a gait pathology involving the knee joint, from a diagnosis of cerebral palsy, muscular dystrophy, spina bifida, or incomplete spinal cord injury.\n* Knee joint range of motion of at least 25 degrees in the sagittal plane (knee extension\u002Fflexion) assessed with hip extended in supine position. Hamstring contracture as assessed by straight leg raising test does not limit ability to participate in the study.\n* Ankle joint range of motion of at least 15 degrees in the sagittal plane (dorsi-plantar flexion) with the foot in neutral alignment.\n* A measured foot-thigh angle of -15 to 30 degrees in prone position.\n* Able to walk at least 10 feet without stopping with or without a walking aid.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Any neurological, musculoskeletal or cardiorespiratory injury, health condition, or diagnosis other than cerebral palsy, muscular dystrophy, spina bifida, or incomplete spinal cord injury that would affect the ability to walk as directed with the robotic exoskeleton.\n* A history of uncontrolled seizure in the past year.\n* Pregnancy. A urine test will be performed for all participants who are able to become pregnant at the initial screening visit and in the case of a positive test, the participant will be excluded from participation. Further monitoring will rely on self-reporting of interruption in menstruation that would require re-testing for pregnancy at the next visit.\n* Any acute cardiopulmonary condition which limits exercise to less than 60 minutes per session or less than 5 days per week.","3 Years","17 Years",{"count":330,"type":21},44,[24],"Background:\n\nPeople with cerebral palsy, spina bifida, muscular dystrophy, or spinal cord injury often have muscle weakness and problems controlling how their legs move. This can affect how they walk. The NIH has designed a robotic device (exoskeleton) that can be worn on the legs while walking. The wearable robot offers a new form of gait training.\n\nObjective:\n\nTo learn whether a robotic device worn on the legs can improve walking ability in those with a gait disorder.\n\nEligibility:\n\nPeople aged 3 to 17 years with a gait disorder involving the knee joint.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam. Their walking ability will be tested.\n\nParticipants will have markers taped on their body; they will walk while cameras record their movements. They will undergo other tests of their motor function and muscle strength.\n\nThe study will be split into three 12-week phases. During 1 phase, participants will continue with their standard therapy.\n\nDuring another phase, participants will work with the exoskeleton in a lab setting. Their legs will be scanned to create an exoskeleton with a customized fit. The exoskeleton operates in different modes: in exercise mode, it applies force that makes it difficult to take steps; in assistance mode, it applies force meant to aid walking; in combination mode, it alternates between these two approaches.\n\nDuring the third phase, participants may take the exoskeleton home. They will walk in the device at least 1 hour per day, 5 days per week, for 12 weeks.\n\nParticipants walking ability will be retested after each phase....",[334,32,335,336],"Cerebral Palsy","Spina Bifida","Incomplete Spinal Cord Injury",[338,339,334,340,341],"EEG","Muscular Dystophies","Knee","incomplete spinal cord injury","2025-10-24",{"date":344,"type":44},"2025-10-27",{"date":346,"type":44},"2023-05-02",{"date":348,"type":21},"2027-10-31",{"name":350,"class":176},"National Institutes of Health Clinical Center (CC)",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":60,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":360,"conditions":361,"keywords":369,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":84},"100063959","myotonic-dystrophy-and-facioscapulohumeral-muscular-dystrophy-registry-100063959","NCT00082108","Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry","National Registry of Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Patients and Family Members","Inclusion Criteria:\n\n* Diagnosed with DM, FSHD, or related diseases or are an unaffected family member of someone diagnosed with one of these diseases",{"count":359,"type":21},3000,"Myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD) are inherited disorders characterized by progressive muscle weakness and loss of muscle tissue. The purpose of this registry is to connect people with DM or FSHD with researchers studying these diseases. The registry will offer individuals with DM and FSHD an opportunity to participate in research that focuses of their diseases. The registry will also help scientists to accomplish research on DM and FSHD and to distribute their findings to patients and care providers.",[69,362,32,363,364,365,366,367,368],"Facioscapulohumeral Muscular Dystrophy","Myotonic Dystrophy Type 1","Myotonic Dystrophy Type 2","Congenital Myotonic Dystrophy","PROMM (Proximal Myotonic Myopathy)","Steinert's Disease","Myotonic Muscular Dystrophy",[370,371,372,32,373,69,374,375,376,377],"Registry","FSHD","DM","Facioscapulohumeral Myotonic Dystrophy","DM1","DM2","FSH","MMD","2025-10-10",{"date":380,"type":44},"2025-10-15",{"date":382,"type":4},"2000-09",{"date":384,"type":21},"2028-06",{"name":386,"class":51},"University of Rochester",{"id":388,"slug":389,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":396,"conditions":397,"keywords":400,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":84},"100068127","genetics-of-cardiovascular-and-neuromuscular-disease-100068127","NCT00138931","Genetics of Cardiovascular and Neuromuscular Disease","Genetic Studies of Patients and Their Families With Inherited Cardiovascular and Neuromuscular Diseases.","Inclusion Criteria:\n\n* Patients of all ages will be considered for the study. In particular, families with more than one affected relative will be sought.\n\nExclusion Criteria:\n\n* Subjects without a suspected inherited cardiovascular or neuromuscular disorder will be excluded from this study.",{"count":395,"type":21},2000,"We are studying the genetics of human cardiovascular and neuromuscular disease. There are many different genetic regions that have been associated with the development of cardiomyopathy. An equal number of genetic regions have been associated with muscular dystrophy and there is overlap because some of the identical genes, when mutated, produce both cardiomyopathy and muscular dystrophy. We are working to identify genes and gene mutations associated with cardiomyopathy, arrhythmias and muscular dystrophy. We propose to screen these samples for mutations in genes known to be involved in these disorders.",[398,399,32],"Cardiomyopathy","Arrhythmia",[398,399,32],"2025-09-05",{"date":403,"type":44},"2025-09-09",{"date":405,"type":4},"1996-09",{"date":407,"type":21},"2030-01",{"name":409,"class":51},"University of Chicago",{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":418,"conditions":419,"keywords":420,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":84},"100081216","clinical-trial-readiness-for-the-dystroglycanopathies-100081216","NCT00313677","Clinical Trial Readiness for the Dystroglycanopathies","Inclusion Criteria:\n\n* Elevated CK (creatine kinase)\n* Evidence of a dystroglycanopathy as determined by review of muscle pathology OR documented mutation in one of the known genes OR abnormal alpha-dystroglycan glycosylation in cultured fibroblasts\n* Dystroglycanopathies are predicted to affect all racial and ethnic backgrounds, and all patients with dystroglycanopathies will be eligible for participation.\n* Participants may be of any age, including children, and males and females will be recruited equally.\n* Patients will have varying degrees of muscular weakness, but otherwise should be in relatively good health.\n\nExclusion Criteria:\n\n* There are no exclusion criteria.",{"count":417,"type":21},190,"The purpose of the study is to describe the early signs and symptoms of the dystroglycanopathies, and to gather information that will be required for future clinical trials.",[32],[193,421,422,423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440,441,442,443,444,445,446,447],"MD","fukutin-related protein gene","limb girdle","FKRP gene","congenital muscular dystrophy","childhood onset LGMD","adult onset LGMD","POMT1","POMT2","POMGnT1","LARGE","alpha dystroglycan","dystroglycanopathy","ISPD\u002FCRPPA","DPM 1, 2 or 3","GMPPB","B3GNT1\u002FB4GAT1","B3GALNT2","GTDC2\u002FPOMGnT2","TMEM5\u002FRXYLT1","Fukutin","DAG1","POMK\u002FSGK196","DOLK","TRAPPC11","GOSR2","INPP5K","2025-07-24",{"date":450,"type":44},"2025-07-30",{"date":452,"type":4},"2006-04",{"date":454,"type":21},"2030-07",{"name":456,"class":51},"Katherine Mathews"]